Last edition
News about "Japan MHLW approval"
Japan Approves Bayer's Sevabertinib for HER2-Mutant NSCLC
Japan approves Bayer’s sevabertinib as the first targeted therapy for HER2-mutant NSCLC, including first-line use, based on phase 1/2 SOHO-01 results.
Japan MHLW Approval | 25/08/2026 | By News Bureau
Biocon's Pegfilgrastim Biosimilar Gets Japan MHLW Approval
Biocon’s pegfilgrastim biosimilar receives Japan MHLW marketing approval, strengthening the company’s biosimilar portfolio and expanding access in Japan.
Japan MHLW Approval | 25/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy